TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02695147

Intervention type: PROCEDURE
Intervention: TAVI

Intervention type: PROCEDURE
Intervention: TAVI
Study: NCT04310332

Intervention type: DRUG
Intervention: 1L-PEG
Description: The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational.

Intervention type: DRUG
Intervention: 4L-PEG
Description: The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational.
Study: NCT00254969

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib
Description: 0.5 mL, Im
Study: NCT00899145

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04467645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflexology
Description: Reflexology is the stimulation of the reflex points in the hands and feet by massage, designed to provide relaxation and relief in the body.
Study: NCT01844726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13
Description: Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection of placebo (saline)
Study: NCT02412449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548 tablet, reference formulation given in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548 tablet, test formulation given in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548 tablet, test formulation given in the fed state
Study: NCT03021551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow sensor
Description: Masimo Radical-7 and Root System with ORi parameter in all subjects are enrolled in the test group and receive an Rainbow sensor during their elective surgery.
Study: NCT03792347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Arm1：Pre-operative Pembrolizumab+chemoradiotherapy
Study: NCT03685682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant subunit Herpes zoster vaccine
Description: Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months
Study: NCT03667118

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food Supplement
Description: A powder blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Food Supplement
Description: A powder blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3
Study: NCT00959010

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 triglycerides
Description: capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules containing middle chain triglycerides
Study: NCT00872001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acadesine
Description: Acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 0.1 mg/kg/min (translating into 1.2 mL/min for a 500 mL solution). In addition, a 5 µg/mL cardioplegia solution of acadesine will be administered, and acadesine will be added to the priming solution (5 µg/mL) in the heart lung machine during CPB.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
Study: NCT03471377

Intervention type: OTHER
Intervention: standard scheduling process
Description: Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long. Depending on the assessment, the scheduling office will either keep the default value, use the value that the surgeon placed in the notes (if available), or the scheduling office provides their own estimation.

Intervention type: OTHER
Intervention: assigned a planned case duration value from predictive model
Description: Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.~Model predictions are then read by scheduling manager sometime between 7am-10am from the SecureShare site, and the scheduling manager will in EPIC/OpTime, overwrite the current estimate with the new duration value that was generated by the predictive model.
Study: NCT04067843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic treatment
Description: Photosensitiser application, followed by fluorescence photography Photodynamic therapy (PHT) (1x) over 15 minutes
Study: NCT01453023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate
Description: 100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: 100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
Study: NCT01354249

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whey protein plus carbohydrate drink
Description: The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein plus carbohydrate drink
Description: The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
Study: NCT01755676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg
Description: 1 tablet 3 times a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet 3 times a day
Study: NCT05988346

Intervention type: PROCEDURE
Intervention: abdominal plastic intervention
Description: According to international guidelines, authors will remove the superficial abdominal fat from the patients enrolled in the study.

Intervention type: PROCEDURE
Intervention: abdominal plastic intervention
Description: According to international guidelines, authors will remove the superficial abdominal fat from the patients enrolled in the study.

Intervention type: PROCEDURE
Intervention: abdominal plastic intervention
Description: According to international guidelines, authors will remove the superficial abdominal fat from the patients enrolled in the study.
Study: NCT04072705

Intervention type: DRUG
Intervention: General principles of care and judgement of researcher
Description: Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.

Intervention type: DRUG
Intervention: General principles of care and judgement of researcher
Description: Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.
Study: NCT03091322

Intervention type: DEVICE
Intervention: Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8
Description: Assessment of the AV Opt and LV VectorOpt features

Intervention type: DEVICE
Intervention: Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8
Description: Assessment of the AV Opt and LV VectorOpt features

Intervention type: DEVICE
Intervention: Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8
Description: Assessment of the AV Opt and LV VectorOpt features

Intervention type: DEVICE
Intervention: Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8
Description: Assessment of the AV Opt and LV VectorOpt features
Study: NCT01150461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: Losartan 50 mg b.i.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo b.i.d.
Study: NCT03105063

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound scan of the hip
Description: validation of Ultrasound test as a tool for diagosing AIIS morphology
Study: NCT02968238

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: 10 weekly sessions of cognitive-behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: 10 weekly sessions of cognitive-behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: 10 weeks of biweekly yoga sessions (N = 20)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: 10 weeks of biweekly yoga sessions (N = 20)
Study: NCT00447590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAP-BAND System
Description: Restriction of food intake
Study: NCT01592396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg
Description: Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 mg, subcutaneously on Day 1.
Study: NCT04324190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided online support program
Description: Guided online support program consisting of several modules; Module General information ... is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided online support program
Description: Guided online support program consisting of several modules; Module General information ... is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WHO recommendations (waiting condition)
Description: During the waiting period, a german translation of the WHO recommendations Coping with stress during the 2019-nCoV outbreak is provided
Study: NCT00491621

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery or biopsy of the kidney tumor
Description: surgery or biopsy of the kidney tumor
Study: NCT03080142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
Study: NCT03430050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
Study: NCT02772718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 358 single dose level A
Description: XOMA 358 single dose level A administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 358 single dose level B
Description: XOMA 358 single dose level B administered by an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 358 single dose level C
Description: XOMA 358 single dose level C administered by an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 358 multiple dose level 1
Description: XOMA 358 multiple dose level 1 administered by an intravenous infusion
Study: NCT04239456

Intervention type: DEVICE
Group type: OTHER
Intervention: RehaCom (software)
Description: RehaCom software has gamified, interactive modules that will help participants practice the application of various memory strategies at custom, increasingly more difficult levels. Instructor will also use the software to teach and demonstrate the use of memory strategies with the domains targeted (i.e., list learning, remembering written/verbal information, and memory for names/faces).
Study: NCT01841697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg oral tablet once a day for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Sitagliptin
Description: Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Metformin
Description: Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label Metformin
Description: Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Glimepiride
Description: Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label Glimepiride
Description: Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
Study: NCT00678483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant (SR141716)
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant (SR141716)
Description: once daily
Study: NCT00719043

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/turkey H5N1 vaccine
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/turkey H5N1 vaccine
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/turkey H5N1 vaccine
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/turkey H5N1 vaccine
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/turkey H5N1 vaccine
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/turkey H5N1 vaccine
Description: Administered as an intramuscular (IM) injection
Study: NCT03729791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
Study: NCT00791700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
Study: NCT01874418

Intervention type: OTHER
Group type: OTHER
Intervention: Biomarker
Description: Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
Study: NCT02074800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328 (Sp2/0-derived)
Description: Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328 (Sp2/0-derived)
Description: Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
Study: NCT00719043

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: A/turkey H5N1 vaccine
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an intramuscular (IM) injection
Study: NCT00813098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX1031 High Dose
Description: A high dose of LX1031; daily oral intake for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX1031 Low Dose
Description: A low dose of LX1031; daily oral intake for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosing with daily oral intake
Study: NCT05225207

Intervention type: OTHER
Intervention: Non-interventional
Description: No intervention will be administered.
Study: NCT03757078

Intervention type: DRUG
Intervention: Relief Pro cream
Description: Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.

Intervention type: DRUG
Intervention: Relief Pro rectal suppositories
Description: Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice
Study: NCT00578162

Intervention type: BEHAVIORAL
Intervention: we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER
Description: A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
Study: NCT00549978

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol
Description: cilostazol, then cilostazol/probucol

Intervention type: DRUG
Group type: OTHER
Intervention: Probucol
Description: Probucol probucol/ cilostazol
Study: NCT01154062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib tablet
Study: NCT02196805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A: imported Probucol ( Lorelco)
Description: Group A: take imported Probucol( Lorelco) (250mg/tablet), Qd, P.O.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B: Marketed Probucol ( Chang Tai)
Description: Group B: take Marketed Probucol(Chang Tai)(250mg/tablet), Qd, P.O.
Study: NCT01233999

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: botulinum toxin A
Description: Botulinum toxin A will be injected into participants hand total 40units